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quency and severity of 10 other features. Liver disease, first 
manifested as non-autoimmune hepatitis, was the common-
est extra-pancreatic feature identified in 85.7% (24/28). 
22/24 had at least one episode of acute hepatic failure which 
was the cause of death in all deceased patients (13/28). One 
child was treated by liver transplantation and had no liver 
disease and better diabetes control for the following 6 years. 
 Conclusions: Liver disease in WRS is more frequent than pre-
viously described and carries high mortality. The first experi-
ence with liver transplantation in WRS is encouraging. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Wolcott-Rallison syndrome (WRS) is a rare condition 
that was initially described in 1972 in siblings with early-
onset diabetes mellitus and skeletal dysplasia (SD)  [1] . 
Further reports extended the phenotype to recurrent hep-
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 Abstract 
 Background: Wolcott-Rallison syndrome (WRS) is caused by 
recessive  EIF2AK3 mutations and characterized by early-on-
set diabetes and skeletal dysplasia. Hepatic dysfunction has 
been reported in 60% of patients.  Aims: To describe a cohort 
of WRS patients and discuss the pattern and management of 
their liver disease.  Methods: Detailed phenotyping and di-
rect sequencing of  EIF2AK3 gene were conducted in all pa-
tients.  Results: Twenty-eight genetically confirmed patients 
(67% male; mean age 4.6 years) were identified. 17 different 
 EIF2AK3 mutations were detected, of which 2 were novel. 
The p.S991N mutation was associated with prolonged sur-
vival and p.I650T with delayed onset. All patients presented 
before 25 months with diabetes with variation in the fre-
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atitis, renal dysfunction, failure to thrive, developmental 
delay, neutropenia and hypothyroidism  [2–7] . Most re-
ported families with WRS originate from the Middle East 
 [8, 9] , and the condition is the commonest cause of per-
manent neonatal diabetes mellitus (PNDM) in consan-
guineous pedigrees  [4] and Arabs  [10] .
 WRS is caused by recessive loss of function mutations 
in the  EIF2AK3 gene  [11] , and almost all reported cases 
have identifiable  mutations. The  EIF2AK3  gene encodes 
a protein called pancreatic PKR-like endoplasmic reticu-
lum kinase (PERK), which plays a key role in detecting 
and initiating the cellular response to endoplasmic reticu-
lum stress. Failure of appropriate PERK response results 
in accumulation of misfolded proteins, which leads to cell 
damage and apoptosis  [12, 13] .
 Liver disease was reported in some patients with WRS 
since 1982  [2–7, 14] . The typical manifestation was inter-
mittent hepatitis precipitated by stress and characterized 
by raised liver transaminase, jaundice and hepatomegaly. 
Acute fatal hepatic failure and chronic hepatic dysfunc-
tion were also reported  [8] . The hepatic histology varied 
from progressive fibrosis with mild steatosis and intrahe-
patic cholestasis  [2] to preserved architecture with mild 
lobular infiltration by lymphocytes and oedema of the 
portal spaces  [15] . The frequency of liver disease was 60% 
in 35 WRS patients reviewed by Ozbek et al. [5] in 2009. 
However, our clinical impression was that liver disease in 
WRS is more frequent and has high mortality. The aim of 
this study was to describe a new cohort of patients with 
WRS and discuss the pattern and management of hepatic 
dysfunction in this cohort.
 Patients and Methods 
 The study was conducted according to the Declaration of 
 Helsinki.
 We searched the database at the Exeter molecular genetics lab-
oratory for genetically confirmed WRS cases referred from Arab 
states until July 2014. Paediatricians in the region were contacted 
to identify unreported WRS cases tested outside Exeter. A ques-
tionnaire on the details of the genotype and phenotype of WRS was 
distributed to the referring physicians of unreported cases and they 
were also requested to provide follow-up data of their reported 
WRS cases. We excluded patients in whom clinical data were in-
complete or if their clinicians did not return the questionnaire. We 
defined liver disease as the presence of at least one episode of non-
infective non-autoimmune hepatitis, unexplained jaundice, hepa-
tomegaly, high liver transaminase, deranged liver function or 
acute hepatic failure (AHF; INR of >1.5 and evidence of impaired 
sensorium). The frequency of liver disease in WRS was expressed 
as the percentage of patients with hepatic dysfunction of the total 
number of the studied cohort.
 Informed consent was signed by the parents, and DNA was 
extracted from the whole blood using the standard methods. Pa-
tients were tested for mutations in the  KCNJ11, ABCC8  INS  and 
 EIF2AK3 genes by Sanger sequence analysis as previously de-
scribed  [4] .
 Results 
 In total, 32 patients were identified. Four patients were 
excluded from the analysis (2 with incomplete follow-up 
data and 2 because their physicians did not return the 
questionnaire). 28 patients (20 families) from 8 Arab 
countries were studied. Of these, 18 were not previously 
described and 10 were initially reported by us in 2009 and 
2011, but remained under follow-up by the same physi-
cians since diagnosis. The genotypes and phenotypes of 
studied patients are shown in  table 1. 
 Clinical Characteristics 
 All patients were the product of consanguineous mar-
riages; their mean age was 4.6 years (range: 10 months to 
17.5 years) and 67% were male. There was a variation in 
the phenotype between patients with the same mutations 
including siblings. Diabetes was the presenting feature in 
all subjects: 25/28 patients have PNDM (onset <6 months 
old; mean age at diagnosis 7.6 weeks) and 3 presented at 
14, 18 and 24 months old. 46.4% of patients were deceased 
(13/28) at a mean age of 5.8 years, and all living subjects 
were on insulin therapy. The longest survived patient in 
the cohort was 17.5 years. Two patients have isolated 
PNDM, and the rest showed at least one extra-pancreatic 
feature ( fig. 1 ).
 Frequency and Pattern of Liver Disease 
 Twenty-four of 28 patients have liver disease, giving 
a frequency rate of 85.7%. The mortality rate in patients 
with liver disease was 54.1% (13/24), and AHF was the 
cause of death in all deceased subjects. During follow-
up of the 10 reported cases, 2 experienced their first 
hepatitis episode and 3 died of AHF. The first presenta-
tion of liver disease in all 24 patients was acute non-
autoimmune hepatitis triggered by viral illnesses and 
characterized by high liver enzymes, jaundice and hepa-
tomegaly. In 6 patients, the hepatitis episodes were as-
sociated with impaired renal function ( table 1 ). Seven 
patients had hepatitis at diagnosis, along with diabetes, 
and the remaining 17 patients experienced their first 
episode between 2 weeks and 2 years after the onset of 
diabetes. In 3 children, the first hepatitis episode pro-
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ceeded to fatal AHF; however, in the remaining 21 pa-
tients the episodes were intermittent, lasting for 3–20 
days, with full recovery except in patient 11.1 who con-
tinued to have persistent hepatomegaly. The highest liv-
er transaminase levels during the episodes varied be-
tween patients from 242 to 50,000 IU/l (mean 8,620). 
22/24 patients experienced at least one episode of AHF. 
Of these, 13 died, 8 recovered with conservative man-
agement and 1 child was treated by liver transplantation 
(LT). This child (13.1) was diagnosed with diabetes at 
14 months old and needed LT at 28 months to treat his 
first AHF. The genetic diagnosis of WRS was subse-
quently confirmed. During a 6-year post-transplant fol-
low-up, he maintained normal liver function without 
hepatitis, and his average HbA1c was 7.8%. He remained 
short due to marked hip and knee deformities; however, 
his average growth velocity over the last 3 years was 
6  cm/year (online suppl. fig. S1; for all online suppl. 
 material, see www.karger.com/doi/10.1159/000369804). 
Liver biopsy was performed between hepatitis episodes 
in 4 patients. In 12.1, 2 and 6, it was for a second opin-
ion and in patient 11.1 for persistent hepatomegaly be-
fore the genetic testing was conducted. The histological 
features were variable between the 4 patients including 
markedly swollen hepatocytes with rarefied cytoplasm, 
occasional necrotic  hepatocytes, minimal fibrosis and 
cholangiopathy.
 Genotype 
 Genetic diagnosis was confirmed in all 28 patients 
( table 1 ). 25 patients were tested in Exeter, while patients 
6.1, 7.1, and 11.1 were tested elsewhere, and the results 
were provided by their physicians. 17 different homozy-
gous  EIF2AK3 mutations were identified of which 2, 
p. S991N and p.G1010D, were novel. Both mutations af-
fect residues that are highly conserved across species, and 
in silico analysis predicts that both substitutions are dis-
ease causing (Alamut Interactive Biosoftware, version 
1.5, Rouen, France). The most frequent mutation, 
p. V349Sfs * 3 (c.1044_1057del), was detected in 3 families 
followed by p.W430X (c.1290G>A) identified in 2 fami-
lies (6 patients from an extended family; online suppl. fig. 
S2). There was no genotype-phenotype correlation apart 
from longer survival of 17.5 years associated with the p.
S991N mutation, and a delayed age at onset of 14 months 
with the p.I650T mutation.
 Discussion 
 We studied the genotype and phenotype of 28 patients 
with WRS from 8 Arab countries. Two novel  EIF2AK3 mu-
tations and 18 new patients were described. This is the first 
study to focus on liver disease in WRS, and it also provides 
long-term data on the first child with WRS to undergo LT. 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Number of patients
7.1%
14.3%
17.8%
21.4%
21.4%
21.4%
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Recurrent hypoglycaemia
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Skeletal dysplasia
Liver disease
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 Fig. 1. Frequency of clinical features of 
WRS in 28 Arab patients expressed as 
 number and percentage of the total patients 
( features reported once are not included). 
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All patients presented with diabetes, and liver disease 
was the commonest extra-pancreatic feature and the 
cause of death in all deceased children. The frequency of 
hepatic disease in our cohort was 85% compared to 60% 
reported by Ozbek et al.  [5] . The most likely explanation 
for the higher frequency of liver disease in our cohort is 
the availability of long-term follow-up data on some of 
our patients. Of the 10 reported patients in this series, 2 
experienced their first hepatitis episode after the initial 
report and 3 died of AHF during follow-up. Of note, our 
patients without liver disease were younger than 3.5 years. 
Considering the disease course in this cohort, we suspect 
that all of them might eventually develop liver disease.
 Children with WRS typically present in the first few 
months of life with diabetes, and it is recommended that 
any child of consanguineous parents presenting with di-
abetes within the first 6 months of life should be tested 
for  EIF2AK3 mutations  [4] . All our patients presented 
with diabetes; however, 3 of them were diagnosed at 14, 
18 and 24 months, making a total number of 4 WRS 
cases with delayed onset reported to date  [3] . We suggest 
that WRS should be considered in children of consan-
guineous families diagnosed with diabetes within the 
first 2 years of life. Of the 4 mutations detected in pa-
tients with delayed presentation, the p.N656K and 
p. I650T missense mutations were only reported in these 
patients and appear to be associated with delayed onset 
of WRS. Both were located close to each other on the 
first kinase domain of PERK protein residue, and the 
p.N656K mutation was shown to have a residual kinase 
activity, which may explain the delayed onset in that pa-
tient  [3] . However, the other 2 mutations (p.W164X and 
p.N42Tfs * 14) were reported in other patients with ear-
ly-onset WRS  [3, 4, 16] . The mean survival age in our 
cohort was 5.8 years, which is similar to the figure re-
ported by Ozbek et al.  [5] . However, a mild course and 
prolonged survival of 32 and 35 years was reported in 2 
patients with the missense mutations p.F593 and p. L646, 
respectively  [3, 4, 14] . Interestingly, our longest surviv-
ing patient of 17.5 years has mild liver disease and was 
homozygous for a novel missense mutation (p. S991N). 
It is possible that these 3 missense mutations are associ-
ated with residual kinase activity of the PERK protein 
resulting in a mild phenotype and prolonged survival; 
however, functional studies are required to clarify this 
hypothesis.
 In agreement with previous reports  [3, 4, 16, 17] , we 
found a variation in the phenotype between patients 
with the same mutation. The exact cause of this phe-
nomenon is still unclear; however, it seems likely that 
other genetic and environmental factors influence the 
tissue response to the mutant PERK protein. Primary 
hypothyroidism (PH) has been recently reported in 3 
patients with WRS  [4, 18, 19] . We add 2 further patients 
(7.1 and 17.1) with PH, supporting the suggestion that 
PH is a new feature of this syndrome. Recurrent hypo-
glycaemia was occasionally described in WRS  [20, 21] , 
and studies in  Perk knockout mice suggested a role of 
impaired hepatic gluconeogenesis  [22] . Despite the high 
frequency of liver disease in our cohort, symptomatic 
hypoglycaemia was only documented in 6 patients with 
liver disease from a family with a p.W430X mutation. 
The only child with this mutation without recurrent hy-
poglycaemia was from a different family and experi-
enced just one episode of hepatitis. It is possible that the 
p.W430X mutation is linked to recurrent hypoglycae-
mia in patients with frequent hepatitis, or the family has 
another predisposing factor for hypoglycaemia. SD is an 
essential criteria of WRS; however, its frequency in our 
cohort was lower than previously described  [2, 5] . It is 
possible that some of our patients were still too young to 
develop it or have no regular skeletal survey to detect 
subtle skeletal changes.
 All our patients with liver disease presented with 
non-autoimmune hepatitis triggered by viral illnesses, 
and most of them recovered completely from the initial 
episodes. However, in 3 children the first hepatitis attack 
proceeded to fatal AHF. This indicates that the course of 
WRS-related hepatitis is unpredictable and that every 
episode should be considered as potentially fatal. WRS-
related hepatitis usually manifest after the onset of dia-
betes; however, Engelmann et al.  [23] described a child 
with WRS in whom the first hepatitis episode developed 
a few months before diabetes, and 25% of our patients 
had hepatitis at initial diagnosis along with diabetes. The 
exact mechanism of liver dysfunction in WRS is un-
known; however, the fact that the episodes are triggered 
by viral illness and other stresses suggest the inability of 
liver cells to deal with endoplasmic reticulum stress due 
to  EIF2AK3  mutations. We noticed a variation in the age 
at onset, frequency, and prognosis of hepatitis between 
patients. The fact that this variation was documented in 
7 children with the p.W430X mutation and 5 patients 
with the p.   V349Sfs * 3 suggests that the severity of liver 
disease is not related to the specific mutation. In this se-
ries, the prognosis of acute liver failure was not related 
to the age, gender or the number of hepatitis episodes 
(results not shown). However, the retrospective nature 
of our study limited our ability to define the role of oth-
er clinical or laboratory variables in the prognosis of 
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 liver disease in WRS. The histological findings in our 4 
patients who had liver biopsy were also variable even 
between children with the same mutation. Although liv-
er biopsy may be useful in understanding the mecha-
nism of liver disease, given the availability of genetic 
testing, we feel that its clinical value in WRS is very lim-
ited.
 The management of liver disease in WRS is a chal-
lenge as the mortality is high and the course is unpre-
dictable. Our practice is to ensure that families recog-
nize the symptoms of hepatitis, and we request parents 
to bring the child to hospital for possible admission if 
he/she develops flu-like illness or other stress. We prefer 
early assessment in a tertiary care liver unit, so a care 
plan is prepared to avoid any delay in starting the man-
agement of AHF. Confirming the genetic diagnosis, 
particularly in patients with first hepatitis episodes or 
atypical features, would avoid the need for invasive tests 
such as liver biopsy. LT has been successfully used in 
some children with hereditary disorders  [24] ; however, 
to the best of our knowledge, its use in WRS has been 
limited to 2 children: the first one was our patient 11.1, 
and the second was a 6-year-old girl described in a re-
cent media report  [25] . Our patient had the transplanta-
tion at 2.4 years of age following his first AHF, and the 
diagnosis of WRS was not confirmed at that time. The 
LT saved his life and appeared to cure the liver disease. 
The improvement of his diabetes control is unlikely to 
be directly related to the LT, but may be reflecting a bet-
ter lifestyle with no recurrent hepatitis. His SD led to 
severe hip and knee deformities, explaining his short 
stature; however, his recent growth was comparable to 
other children with liver transplant  [26] . Our experi-
ence with this child suggests that LT would be a success-
ful therapy for WRS patients; however, more data are 
needed to make it a standard treatment for WRS. As 
WRS affects other organs such as pancreatic β-cell and 
kidneys, combined organ transplant may be an option 
for these patients. Clearly, the decision of transplanta-
tion should take into account the neurocognitive func-
tion of the child as some WRS patients have significant 
neurodevelopmental delay.
 In conclusion, WRS should be considered in children 
of consanguineous families diagnosed with diabetes with-
in the first 2 years of life. In this condition, liver disease is 
more common than previously reported, has unpredict-
able course and carries high mortality. The first experi-
ence of LT in WRS is encouraging.
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